Antibacterial application of vitamin D and composition thereof

A technology of vitamins and compositions, applied in the field of vitamin D compounds

Pending Publication Date: 2020-11-10
ZENSUN (SHANGHAI) SCI & TECH CO LTD
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

At the same time, due to the rapid growth of drug-resistant pathogenic microorganisms caused by the extensive use of traditional antibiotics, it is urgent to develop new antibiotics to deal with the increasingly serious drug resistance of pathogenic microorganisms worldwide.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Antibacterial application of vitamin D and composition thereof
  • Antibacterial application of vitamin D and composition thereof
  • Antibacterial application of vitamin D and composition thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0040] Example 1: 1α,25-(OH)2D3 (active form of vitamin D3) induces infection of E. coli T24 cells

[0041] Concentration detection of secreted LL37 antimicrobial peptide

[0042] 1 Purpose of the study

[0043] The purpose of this study was to investigate active vitamin D3 (1α,25-(OH) 2 D 3 ) whether pretreatment of urothelial cells can promote the cells to produce enough antimicrobial peptide LL37 to inhibit the infection of pathogenic E. 3 To provide a pharmacodynamic experimental basis for the treatment of recurrent lower urinary tract infections, and to clarify the quantitative relationship between the dose of vitamin D3 and the local secretion of antimicrobial peptides by the bladder epithelium.

[0044] 2 Experimental materials

[0045] 2.1 Test article

[0046] 1α,25-(OH) 2 D 3 (Vitamin D 3 active form)

[0047] Manufacturer: Sigma-Aldrich Purity: ≥99% (HPLC)

[0048] 2.2 Experimental cells and strains

[0049] 2.2.1 Experimental cells

[0050] T24 cells we...

Embodiment 2

[0092] Example 2: Evaluation of the in vitro antibacterial effect of antimicrobial peptide LL37 on common pathogenic bacteria isolated from clinical urinary tract in my country in the past three years

[0093] 1 Purpose of the study

[0094] To evaluate the in vitro antibacterial effect of antimicrobial peptide LL37 on common pathogenic bacteria isolated from clinical urinary tract in my country in the past three years.

[0095] 2 Test drugs

[0096] LL37: potency: 98.51%, Shanghai Zesheng Technology Development Co., Ltd.;

[0097] 3 Test strains

[0098] 3.1 Standard strain: Enterococcus faecalis ATCC29212, WHO14;

[0099] Enterococcus faecium ATCC700221;

[0100] Escherichia coli ATCC25922, ATCC35218.

[0101] 3.2 Clinical isolates: 76 clinical isolates from urinary tract were collected nationwide from 2015 to 2017, some of which were vancomycin-resistant Enterococcus faecium from 2013 and 2014, including:

[0102] 11 strains of vancomycin-sensitive Enterococcus faecal...

Embodiment 3

[0132] Example 3: Bacteriostatic ability of 1α,25-(OH)2D3 (active form of vitamin D3) on three cells (T24 cells, 5637 cells and SV-HUC-1 cells) infected with Escherichia coli

[0133] 1 Purpose of the study

[0134] The purpose of this study was to investigate active vitamin D3 (1α,25-(OH) 2 D 3 ) pretreatment of urothelial cells can inhibit the infection of the cells by pathogenic E. coli CFTO73, so that vitamin D 3 Pharmacodynamic experiments are provided for the treatment of recurrent lower urinary tract infections.

[0135] 2 Experimental materials

[0136] 2.1 Test article

[0137] 1α,25-(OH) 2 D 3 (Vitamin D 3 active form)

[0138] Manufacturer: Sigma-Aldrich Item No.: D1530 Purity: ≥99% (HPLC)

[0139] 2.2 Experimental cells and strains

[0140] 2.2.1 Experimental cells

[0141] 5637 cells and T24 cells were purchased from the cell bank of the Type Culture Collection Committee of the Chinese Academy of Sciences. The culture conditions were 1640 medium contai...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to an application of a vitamin D compound to preparation of a medicine for preventing or treating cystitis, urethritis and / or urinary tract infection, in particular to a medicinecomposition and medicine preparation for preventing or treating cystitis, urethritis and / or urinary tract infection.

Description

technical field [0001] The present invention relates to the use of vitamin D compounds in the preparation of medicaments for preventing or treating cystitis, urethritis and / or urinary tract infection. More particularly, it relates to pharmaceutical compositions and pharmaceutical preparations for the prevention or treatment of cystitis, urethritis and / or urinary tract infections. Background technique [0002] Urinary tract infection (UTI), also known as urinary tract infection, is an inflammation caused by pathogenic bacteria invading the urinary tract, growing and multiplying in the urine, and infecting the mucosa or tissue of the urinary tract. Urinary tract infection (UTI) is a multiple disease, ranking second only to respiratory tract infection among infectious diseases, and it is also one of the most common infectious diseases in adults. Worldwide, more than 150 million people are infected each year. In the United States, more than 8 million people visit a doctor and ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/592A61K31/593A61K45/06A61P13/02A61P13/10A61P13/12A61P31/04
CPCA61K31/592A61K31/593A61K45/06A61P13/02A61P13/10A61P13/12A61P31/04A61K2300/00Y02A50/30
Inventor 周明东
Owner ZENSUN (SHANGHAI) SCI & TECH CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap